The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

In a strategic pivot, the company has launched its weight-loss program in the United Kingdom. There, Hims & Hers is offering legitimate, branded medications—Novo Nordisk's Wegovy and Eli Lilly's ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will ...

Online telehealth company Hims and Hers Health is launching weight-loss membership and treatment plans in the UK. The new service will offer drugs such as Novo Nordisk's Wegovy and Eli Lilly's ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...